Lipocine (LPCN) Gains from Investment Securities (2016 - 2025)
Lipocine's Gains from Investment Securities history spans 11 years, with the latest figure at $5870.0 for Q3 2025.
- For Q3 2025, Gains from Investment Securities fell 66.76% year-over-year to $5870.0; the TTM value through Sep 2025 reached $24414.0, up 112.53%, while the annual FY2024 figure was $335258.0, 27.84% up from the prior year.
- Gains from Investment Securities reached $5870.0 in Q3 2025 per LPCN's latest filing, down from $349616.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $4.0 million in Q3 2022 to a low of -$356090.0 in Q4 2021.
- Average Gains from Investment Securities over 5 years is $768171.2, with a median of $11764.5 recorded in 2024.
- The largest YoY upside for Gains from Investment Securities was 10130926.32% in 2021 against a maximum downside of 21674.04% in 2021.
- A 5-year view of Gains from Investment Securities shows it stood at -$356090.0 in 2021, then soared by 249.37% to $531897.0 in 2022, then crashed by 140.11% to -$213346.0 in 2023, then soared by 108.28% to $17659.0 in 2024, then crashed by 66.76% to $5870.0 in 2025.
- Per Business Quant, the three most recent readings for LPCN's Gains from Investment Securities are $5870.0 (Q3 2025), $349616.0 (Q1 2025), and $17659.0 (Q3 2024).